• Cell Therapeutics Inc., of Seattle, said it will sell $40 million of shares of Series 15 convertible preferred stock and warrants to purchase shares of common stock in a registered direct offering to an institutional investor in two tranches of $20 million each. The net proceeds will be used to finance the purchase of pacritinib from Singapore-based S*BIO Pte Ltd. and for the commercial launch of Pixuvri (pixantrone) in the European Union. (See BioWorld Today, April 20, 2012.)

• Depomed Inc., of Menlo Park, Calif., filed a shelf registration statement with the SEC to replace its previously filed shelf registration statement, due to expire in June. It includes registration for the sale of common stock, preferred stock and debt securities. The company does not currently have a plan to issue securities under the registration statement.